2004
DOI: 10.1016/s0210-4806(04)73078-8
|View full text |Cite
|
Sign up to set email alerts
|

Valor pronóstico de la ploidía del adn y la morfometría nuclear en el cáncer de próstata metastásico

Abstract: The study of DNA content and nuclear morphometry in the primitive tumor provides independent prognostic information in survival analysis for patients with metastatic prostate cancer. However, there is limited improvement with respect to the classical factors in predicting survival. This questions its utility in the daily clinical usage.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2006
2006
2007
2007

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 31 publications
0
1
0
Order By: Relevance
“…The results of the study by Martinez- Jabaloyas et al (77) revealed that mean nuclear area and other factors proved to have a prognostic value in the univariate analysis and concluded (78) that nuclear morphometry in the primitive tumor provides independent prognostic information in survival analysis for patients with metastatic prostate cancer. The combined evaluation of high nuclear morphology, ploidy, and cell survival parameters such as Bcl- 2 expression might better identify patients with poor prognosis among early stage prostate carcinomas diagnosed by FNA biopsies (79).…”
mentioning
confidence: 99%
“…The results of the study by Martinez- Jabaloyas et al (77) revealed that mean nuclear area and other factors proved to have a prognostic value in the univariate analysis and concluded (78) that nuclear morphometry in the primitive tumor provides independent prognostic information in survival analysis for patients with metastatic prostate cancer. The combined evaluation of high nuclear morphology, ploidy, and cell survival parameters such as Bcl- 2 expression might better identify patients with poor prognosis among early stage prostate carcinomas diagnosed by FNA biopsies (79).…”
mentioning
confidence: 99%